Introducing FlexFactory to Poland, delivered by Cytiva and operated by SyVento Biotech

SyVento Biotech has opened its new mRNA manufacturing facility, a FlexFactory delivered by Cytiva, spanning over 7 000 m2, including lab and production areas, offices, and shared spaces. This development represents a significant milestone for SyVento Biotech, enabling the CDMO to accelerate and enhance their service offerings to medicine manufacturers.   

It also establishes SyVento Biotech as a pioneer in the Polish market as it is the first mRNA FlexFactory in the country and the first in Europe equipped with the Historian automation system.   

Dominik Lipka, Chief Technology Officer, SyVento Biotech, says: “We offer a one stop-shop for our partners and clients, so they can produce new mRNA therapies from lab scale to commercial production – whether that is large batch or small, personalized batch.  Bringing this FlexFactory to Poland, the center point of Europe, makes new therapies available to patients in an efficient and high-quality way.”  

The FlexFactory, an end-to-end platform, integrates technologies including crucial encapsulation steps from Cytiva’s nanomedicines business (formerly Precision NanoSystems) and single-use consumables for filling processes. In addition, the Historian automation system speeds the collection, aggregation, centralization, and archiving of manufacturing data, enabling data integrity and compliance, thereby setting a new standard for manufacturing efficiency and reliability.  

Ludovic Brellier, President of Hardware Solutions, Cytiva, says: “Cytiva and SyVento Biotech are wholly committed to fostering innovation and growth in the biotechnology sector. We have a shared vision of supporting the development of cutting-edge therapies to ensure that they reach patients more efficiently and effectively.”  

SyVento Biotech is planning a celebration of its GMP-certified facility in May 2025. For more information about SyVento Biotech, please visit SyVento Biotech.   

### 

About Cytiva 

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With  

15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provide critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com.  

About Syvento 

SyVento is a biotech CDMO in the segment of mRNA and lipids nanoparticle formulations (LNP). 
The Company develops and manufactures mRNA and advanced lipid nanocarriers from the newest, state-of-the-art, GMP-certified production facility.